Isofol Medical AB (OSTO:ISOFOL) Current Accrued Expense: kr17.66 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ISOFOL Isofol Medical AB OSTO:ISOFOL
18 GF Score
Price kr0.74
! 2 Warning Signs
View Full Analysis

What is Isofol Medical AB Current Accrued Expense?

Isofol Medical AB OSTO:ISOFOL +1.37% 18 Current Accrued Expense is kr17.66 Mil as of Jun. 2026. GuruFocus rates OSTO:ISOFOL with a GF Score™ of 18/100. The stock has 2 warning signs investors should review.

Isofol Medical AB's Current Accrued Expense for the quarter that ended in Jun. 2026 was kr17.66 Mil.

Isofol Medical AB's quarterly Current Accrued Expense increased from Dec. 2025 (kr14.04 Mil) to Mar. 2026 (kr17.24 Mil) and increased from Mar. 2026 (kr17.24 Mil) to Jun. 2026 (kr17.66 Mil).

Isofol Medical AB's annual Current Accrued Expense increased from Dec. 2023 (kr14.80 Mil) to Dec. 2024 (kr15.29 Mil) but then declined from Dec. 2024 (kr15.29 Mil) to Dec. 2025 (kr14.04 Mil).

Isofol Medical AB Current Accrued Expense Related Terms

Isofol Medical AB Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Isofol Medical AB's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Isofol Medical AB Current Accrued Expense Chart

Isofol Medical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 54.82 27.19 14.80 15.29 14.04

Isofol Medical AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.90 17.46 14.04 17.24 17.66
OSTO:ISOFOL
18GF Score
Isofol Medical AB OSTO:ISOFOL
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Isofol Medical AB Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of kr17.66 Mil mean?
Isofol Medical AB (OSTO:ISOFOL) has a Current Accrued Expense of kr17.66 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Isofol Medical AB and its competitors.
Is Isofol Medical AB's Current Accrued Expense too high?
Isofol Medical AB's current Current Accrued Expense is kr17.66 Mil. Overall, Isofol Medical AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Isofol Medical AB's Current Accrued Expense compare to VRTX and REGN?
Isofol Medical AB's Current Accrued Expense of kr17.66 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Isofol Medical AB and its competitors. Isofol Medical AB's current Current Accrued Expense is kr17.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Isofol Medical AB stock overvalued right now?
Isofol Medical AB (OSTO:ISOFOL) has a current Current Accrued Expense of kr17.66 Mil. The current Current Accrued Expense is kr17.66 Mil. Isofol Medical AB's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Isofol Medical AB (OSTO:ISOFOL), the current Current Accrued Expense is kr17.66 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Isofol Medical AB Business Description

Address Arvid Wallgrens Backe 20, Biotech Center, Gothenburg, SWE, SE-413 46
Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.
18GF Score

Get the complete analysis for OSTO:ISOFOL

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.74
Price